DNRS 6630 Week 4 Drug Class Comparison Example

Course	DNRS 6630 Psychopharmacologic Approaches to Treatment of Psychopathology
Week	Week 4
Paper type	Drug class comparison paper
Length	About 770 words, 5 pages
Format	APA 7 student paper
School	Walden University
Program	Doctor of Nursing Practice (DNP)
Updated	October 2026

Free sample paper for DNRS 6630 Week 4

Drug Class Comparison: Orexin Receptor Antagonists and Nonbenzodiazepine Receptor Agonists for Chronic Insomnia in a 72-Year-Old Woman

Student Name

College of Nursing, Walden University

DNRS 6630: Psychopharmacologic Approaches to Treatment of Psychopathology

Instructor Name

Month Day, Year

What this page is doingThe title names two classes and one person. A comparison that stays symmetrical to the end never has to commit, and naming the person signals that this one will.

Drug Class Comparison: Orexin Receptor Antagonists and Nonbenzodiazepine Receptor Agonists for Chronic Insomnia in a 72-Year-Old Woman

The Comparison

The two classes are compared on five columns. Every cell carries its source, and the prose that follows reads the columns rather than replacing them.

Table 1

Two Hypnotic Classes Compared for Chronic Insomnia Disorder

Class	Proposed mechanism	Evidence base and designs	Tolerability, by category	Monitoring burden on a clinic	Access
Nonbenzodiazepine receptor agonists	Positive modulation of GABA-A receptors, enhancing inhibitory signaling (Sateia et al., 2017)	Many short randomized trials; network meta-analysis of 154 double-blind trials; long-term data limited (De Crescenzo et al., 2022)	Next-day sedation, falls, cognitive effects, complex sleep behaviors (U.S. Food and Drug Administration [FDA], 2019)	Fall and confusion review at every visit; screening for complex sleep behaviors; plan to limit duration	Generic, low cost; no prior authorization in most plans
Orexin receptor antagonists	Blocking orexin, a wake-promoting signal, rather than enhancing sedation (Sateia et al., 2017)	Fewer randomized trials, some up to a year; network meta-analysis found long-term efficacy for one agent and inconclusive safety data (De Crescenzo et al., 2022)	Somnolence; fewer dropouts from adverse events than some older hypnotics in the same analysis (De Crescenzo et al., 2022)	Somnolence and daytime function check; no specific laboratory monitoring	Brand-only; often prior authorization and higher cost sharing

Reading the Table

The presenting problem: a composite 72-year-old woman with 2 years of difficulty staying asleep, who completed a course of cognitive behavioral therapy for insomnia with partial benefit, the recommended first step (Qaseem et al., 2016), and now asks for medication. She lives alone, fell once last winter, and says her priority is not feeling foggy in the morning because she drives her grandchildren to school.

Reading the evidence columns against each other, the older class has the larger literature, but volume is not quality. Most of its trials are short, and for long-term use the network meta-analysis rated the evidence for every agent as very low certainty (De Crescenzo et al., 2022). The newer class has fewer trials, but some run longer, closer to how she would actually use the drug. Neither class has strong evidence for years of use.

Reading tolerability against what she has said matters, the columns separate. The older class's known risks, next-day impairment, falls, and complex sleep behaviors serious enough to prompt a boxed warning (FDA, 2019), fall exactly on her two priorities: not falling and not driving impaired. The Beers Criteria advise avoiding the older class in adults her age for these reasons (American Geriatrics Society Beers Criteria Update Expert Panel, 2023). The newer class's main problem, somnolence, overlaps with her concern, but less of its known harm lands on falls and unusual night behavior.

What this page is doingThe prose reads the columns against each other and against what the person said matters. It refuses to let the size of a literature stand in for its quality, which is the judgment this week grades.

What the Table Leaves Out

Two things sit outside the five columns and still shape the decision. The first is whether something other than insomnia disorder explains her waking. Untreated sleep apnea, nocturia, pain, and depression all fragment sleep in later life, and any hypnotic that deepens sedation could worsen breathing during sleep in someone with undiagnosed apnea. Before either class is started, she is asked about snoring and witnessed pauses, and her nighttime urination and mood are reviewed. The second is how long she expects to take it. The guidelines that support either class describe the evidence as weak and short term (Sateia et al., 2017), so the plan is framed from the start as a trial with a review date rather than an open-ended prescription. Both points apply to either class, which is why they are not columns, but a comparison that ignored them could reach the right class for the wrong patient.

The Commitment

For this woman, I would choose the orexin receptor antagonist class, continued alongside the behavioral strategies she learned, and reviewed at 4 weeks for sleep, morning alertness, and any fall. The decision rests on tolerability read against her priorities, not on efficacy, where the two classes are closer than their literatures suggest. Access is the cost of the choice: a prior authorization request will be needed, and the clinic takes that burden on rather than passing it to her.

What Would Reverse the Choice

The choice reverses if she reports morning grogginess that affects driving despite a correctly timed dose, if the plan's prior authorization is denied on appeal and the cost is beyond her means, or if new evidence of harm with the newer class emerges. In the first two cases, the next step is not the older class by default but a return to the behavioral program with a booster session, since the reasons for avoiding the older class in her remain.

References

American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372

De Crescenzo, F., D'Alò, G. L., Ostinelli, E. G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F., Del Giovane, C., Quested, D. J., Cowen, P. J., Barbui, C., Amato, L., Efthimiou, O., & Cipriani, A. (2022). Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: A systematic review and network meta-analysis. The Lancet, 400(10347), 170-184. https://doi.org/10.1016/S0140-6736(22)00878-9

Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & Clinical Guidelines Committee of the American College of Physicians. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133. https://doi.org/10.7326/M15-2175

Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307-349. https://doi.org/10.5664/jcsm.6470

U.S. Food and Drug Administration. (2019). FDA adds boxed warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines [Drug safety communication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia

The Walden DNRS 6630 Week 4 instructions

In Week 4 the DNRS 6630 prompt typically names a condition and two medication classes and asks which suits a described patient better. You compare them on agreed dimensions such as efficacy, onset, adverse effects, interactions and risks specific to the patient, then make and defend a choice. A comparison table is often encouraged, but faculty want the narrative to interpret it. A DNRS 6630 comparison usually fills four or five APA pages and cites guidelines and comparative evidence rather than drug monographs alone. Patient factors, here age and fall risk, should drive the decision. Many instructors also ask what would make you switch to the other class. Read whether your section wants named agents or classes only, because some keep the discussion at class level on purpose.

How the DNRS 6630 Week 4 example is put together

The table has the two classes as rows and five columns: proposed mechanism, the evidence base with its study designs named, tolerability grouped into categories rather than listed exhaustively, monitoring burden expressed as what it obliges a clinic to arrange, and access. Every cell carries a citation, and the table is followed rather than replaced by prose. Four paragraphs sit underneath. One restates the presenting problem in a line. One reads the evidence columns against each other and refuses to treat volume of literature as quality. One reads tolerability against what the composite person has said matters to them. The last commits, and a closing paragraph names what would reverse the choice.

Reading the DNRS 6630 Week 4 rubric

A paper that will not choose is the specific weakness this week was built to surface, and it turns up constantly. Work laying both classes out evenly and concluding that either could be appropriate has answered a question nobody asked. Credit follows the commitment and the reasoning attached to it, then the quality of the evidence reading, where counting studies rather than weighing designs costs across the analysis area. Tolerability columns copied wholesale from a reference read as transcription and earn accordingly. Access and monitoring burden are the columns most often left thin, and markers notice because they are the two that determine whether anything proposed could actually happen. Formatting weight is higher than usual in this week, since a table that will not align damages readability everywhere.

DNRS 6630 Week 4 help: mistakes that cost marks

The weakness this week exposes most is a paper that lays both classes out evenly and then declines to choose. Commit, and say which column decided it. A second common problem is a table whose cells carry no sources, which leaves every claim unsupported. Writers also let the prose restate the table line by line instead of explaining what the columns mean together. Keep the patient in view: a 72-year-old with a fall history changes the weight of next-day sedation. Avoid presenting network meta-analysis rankings as if they were head-to-head trials. Make sure the Beers Criteria year in the text matches the reference list. Close with the specific observation, such as a fall or morning grogginess, that would move you to the other class.

Get a DNRS 6630 Week 4 example written to your instructions

Give the desk the two classes your prompt names, the presenting problem it fixes and any table format the section supplies, and a completed comparison comes back in that format. The first custom one is free and returns within 24 to 48 hours. What arrives carries the structure and the sourcing, and prescribing particulars stay in the classroom where they belong.

More DNRS 6630 papers and DNP samples

DNRS 6630 Week 4 questions, answered

Why are the two classes left unnamed here?

Because what transfers between one comparison and another is the shape of the argument, not its contents, and because sections assign different pairs anyway. A page naming classes would also be publishing prescribing material for anyone to read. The columns, the ordering and the commitment paragraph are what this example is worth reading for, and they hold whichever pair a prompt sets.

Should the table repeat what the narrative says?

It should not, and papers lose readability credit when it does. The table holds the compressed comparison and the narrative reads it, which means the prose spends its words on judgment rather than on restating cells. A useful test is whether any paragraph could be deleted without loss because the table already said it plainly.

How much evidence does a class comparison need?

Enough that each cell in the evidence column rests on something identifiable, which in this example means naming study designs rather than counting citations. Reviews are used where they summarize a field and primary work is used where a specific claim depends on it. Prompts vary in what they require, and the reference expectations in your classroom are the ones that govern.

Where can I find a free DNRS 6630 Week 4 sample paper?

The orexin antagonist versus Z-drug comparison sits on this page with its sourced table, the reading of each column, the commitment and the reversal condition.

Which insomnia drug class does the DNRS 6630 Week 4 example choose?

It commits to the orexin receptor antagonists for this older woman, mainly on fall risk and next-morning impairment, and names what would send it back to the other class.